Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
|
|
- Osborn Cummings
- 7 years ago
- Views:
Transcription
1 December 18, 2012 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD Re: Comments on Docket No. FDA 2012 N 1037; Establishing a List of Qualifying Pathogens That Have the Potential to Pose a Serious Threat to Public Health Dear Sir/Madam: The Infectious Diseases Society of America (IDSA) is pleased to submit comments for the above referenced Food and Drug Administration (FDA) public hearing on establishing a list of qualifying pathogens that have the potential to pose a serious threat to public health. IDSA represents nearly 10,000 infectious diseases physicians and scientists devoted to patient care, prevention, public health, education, and research in the area of infectious diseases. Our members care for patients of all ages with serious infections, including meningitis, pneumonia, tuberculosis, HIV/AIDS, antibiotic-resistant bacterial infections such as those caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and Gram-negative bacterial infections such as Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa, and emerging infections such as the 2009 H1N1 influenza virus. IDSA recognizes the importance of targeting incentives to the areas of greatest unmet medical need. With this goal in mind, IDSA is pleased to address the specific questions posed by FDA. 1. The Food and Drug Administration Safety and Innovation Act (FDASIA) requires FDA to consider the following factors in establishing and maintaining the list of qualifying pathogens: The impact on the public health due to drug-resistant organisms in humans; The rate of growth of drug-resistant organisms in humans; The increase in resistance rates in humans; and The morbidity and mortality in humans. How should these factors be applied to a pathogen to determine whether it should be included in the list?
2 PAGE TWO IDSA Comments on Establishing a List of Qualifying Pathogens In determining a pathogen s impact on the public health, FDA should consider the current incidence of infection with resistant strains of this pathogen. Further, FDA should consider the prevalence of colonization with this pathogen to the extent that colonization is a predisposing factor for infection of the colonized individual or others. The impact on public health should also consider ease of transmission. Another factor in a resistant pathogen s potential to impact public health is the availability of effective, evidence-based prevention measures that reduce the risk of spread of the resistant pathogen. Resistant pathogens for which proven and easily deployable interventions to prevent spread exist (e.g., immunization), would likely pose less of a threat than those for which interventions to prevent spread are less effective or difficult to deploy (e.g., universal screening, contact precautions and cohorting of colonized patients). In analyzing these factors, FDA should consider practical experience in the clinical care and public health systems as well as whether sufficient operational capacity exists to successfully implement preventive interventions. The rate of increase of growth of drug-resistant organisms in humans and the increase in resistance rates in humans are critical factors as well. To the extent possible, FDA should consider a ten-year projected incidence of infection (or prevalence of colonization) with individual pathogens based on their current trajectory of spread, or potential trajectory of spread based on experience with other similar resistant pathogens. FDA also should consider the potential ease with which genetic determinants conferring resistance transfer to pathogens from other organisms. To determine whether a resistant pathogen poses an excess burden of morbidity and mortality, FDA should consider various measures, including hospital length of stay, courses of antimicrobial therapy, need for additional medical interventions or rehabilitative therapies, temporary or permanent disability, and days lost from work or school. 2. Aside from the considerations noted in question 1 (i.e., those required by section 505(E)(f)(2)(B)(i) of the FD&C Act), are there any other factors FDA should consider when establishing and maintaining the list of qualifying pathogens? If so, how should these factors be applied to a pathogen to determine whether it should be included in the list? IDSA encourages FDA to consider the availability of safe and effective therapeutic options to treat infections caused by resistant pathogens. Pathogens for which there are no or very limited treatments or for which the only available, effective treatments present significant toxicities should receive high priority. In addition, pathogens that have demonstrated the capacity to quickly develop resistance to alternative therapy should be high priorities. FDA should consider the financial impact of the emergence and spread of resistant pathogens. Costs should be measured from the societal perspective, including direct and indirect costs of infection (including health care costs and lost productivity), as well as activities that may need to be undertaken to prevent spread of infection.
3 PAGE THREE IDSA Comments on Establishing a List of Qualifying Pathogens FDA also should consider the extent to which a pathogen is resistant and the impact of resistance on clinical care. The greatest medical need is for agents to treat pathogens that are extensively drug-resistant (XDR) and pan-drug-resistant (PDR). 3. Which specific pathogens do you believe should be listed as qualifying pathogens? Provide justification for your recommendations, including how you applied the considerations described in section 505E(f)(2)(B)(i) of the FD&C Act, and any other factors that you considered, in recommending the pathogen for inclusion on the list of qualifying pathogens. ESKAPE Pathogens: The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Escherichia coli and Enterobacter species) cause serious and life-threatening infections, are extremely difficult and in many cases impossible to effectively treat, and clearly meet the required criteria for qualifying pathogens. 1 ESKAPE pathogens currently cause the majority of U.S. hospital infections and effectively escape the effects of available drugs. 2 More people now die of MRSA infection in U.S. hospitals than of HIV/AIDS and tuberculosis combined. 3 While some intravenous treatment options for MRSA exist, oral agents are desperately needed. XDR Klebsiella or XDR Acinetobacter bacteria kill up to 50% of infected patients despite treatment with last resort drugs, and resistance rates for these pathogens continue to climb. Therapeutic options for ESKAPE pathogens are extremely limited such that clinicians are often forced to use obsolete drugs, such as colistin, that are associated with significant toxicity and for which there is a lack of robust data to guide dosage regimen or duration of therapy. 4 For example, all strains of Klebsiella and E. coli containing the New Delhi metallo-beta-lactamase (NDM-1) (see more below) enzyme are resistant to all antibiotics except colistin and tigecycline, and 10% of these strains are even resistant to these drugs, making them truly pan resistant. 5 XDR Acinetobacter strains that are resistant to colistin are now being reported. Clostridium Difficile: C. difficile causes diarrhea linked to 14,000 American deaths each year. The incidence, deaths, and excess health-care costs resulting from C. difficile in hospitalized patients are at historic highs. From 2000 to 2009, the number of hospitalized patients with C. difficile infection (CDI) discharge diagnoses more than doubled, and the number with a primary CDI diagnosis more than tripled. Deaths related to C. difficile increased 400% between 2000 and Much of the recent increase in the incidence and mortality of CDIs is attributed to the 1 Combating Antimicrobial Resistance: Policy Recommendations to Save Lives, Clin Inf Dis; 2011; Boucher, Helen; Talbot, George; Bradley, John; Edwards Jr., John; Gilbert, David; Rice, Louis; Scheld, Michael; Spellberg, Brad; Bartlett, John. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America, Clin Inf Dis 2009; 48: Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, Clin Inf Dis 2006; 42: Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gramnegative bacterial infections. Clin Inf Dis 2005; 40: Kumarasamy 10 Lancet Infectious Diseases 10:
4 PAGE FOUR IDSA Comments on Establishing a List of Qualifying Pathogens emergence and spread of a hypervirulent, resistant strain of C. difficile. CDI is a serious threat not only in hospitals, but across the health care continuum. In fact, about 75% of CDIs first show symptoms in nursing home patients or in people recently cared for in doctors offices and clinics. Because C. difficile can live for long periods on surfaces it is easily transmitted from patient to patient. 6 Multidrug-Resistant Tuberculosis (MDR TB) and Extensively Drug-Resistant Tuberculosis (XDR TB): MDR TB is resistant to at least isoniazid and rifampin, the two most potent TB drugs. XDR-TB is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). Patients with these forms of TB must be treated with less effective and more toxic regimens. Infection with highly resistant strains of M. tuberculosis are of special concern for people with Human Immunodeficiency Virus (HIV) infection or other conditions that can weaken the immune system. They are more likely to develop TB disease, and also have a higher risk of death. Curing resistant TB can cost 200 times as much as curing typical TB; it also can take years, and some of the drugs cause side effects like deafness and psychosis. Resistant TB is a growing problem. A study published in The Lancet in October 2012 concerning more than 1,200 TB patients in 7 countries found that 44 percent of the TB strains identified showed resistance to at least one second-line drug. Although many of the most serious resistant TB cases occur in foreign countries, our increasingly global economy and high levels of international travel make this a threat the U.S. cannot ignore. Neisseria gonorrhoeae: Neisseria gonorrhoeae has demonstrated the ability to develop resistance to almost every antibiotic recommended for treatment: sulfonamides, tetracycline, penicillin, and, most recently, fluoroquinolones. CDC s surveillance is now showing disturbing trends of decreasing susceptibility to cephalosporins the last line of defense for treating gonorrhea. Actual treatment failures have been reported in other parts of the world, raising concerns that strains of gonorrhea with decreased susceptibility will be imported into the U.S. by travelers. Multi-drug resistant gonorrhea would have substantial health and economic consequences. First, there would be an increase in gonorrhea rates in the population, because people with gonorrhea will remain infectious for a longer period of time. Modeling studies suggests that gonorrhea prevalence in the population could increase by 7% to 40% per year as a result of antimicrobial resistance developing in a population without additional therapies. This would lead to increases in pelvic inflammatory disease in women (estimated cost, $585 million) and epididymitis in men (estimated cost, $15 million). Second, because gonorrhea can facilitate the acquisition and transmission of HIV, the increase in gonorrhea prevalence could lead to increases in new HIV infections as well (estimated cost, $180 million). 7 6 Vital Signs: Preventing Clostridium difficile Infections, Morbidity and Mortality Weekly Report (MMWR); Centers for Disease Control and Prevention (CDC); March 9, 2012 / 61(09); Potential Emergence of Multi-Drug Resistant Gonorrhea, Fact sheet from the Centers for Disease Control and Prevention (CDC), Dec
5 PAGE FIVE IDSA Comments on Establishing a List of Qualifying Pathogens Emerging Infections: FDASIA provides mechanisms for FDA to periodically review the list of qualifying pathogens and make updates as new threats emerge. IDSA urges FDA to monitor the following emerging pathogens that may become serious threats in the coming years. Non-ESKAPE pathogens containing the NDM-1 enzyme Enteric pathogens developing greater resistance, including Salmonella and Shigella including fluoroquinolone-resistant strains and ESBL, carbapenemase, or NDM-1 containing strains Carbapenem-resistant Enterobacteriaceae (CRE) Resistant pathogens emerging in other countries that demonstrate the potential for a serious public health impact given the globalization of our society and the ease for infection to spread through international travel Fungal infections: Candida species are the third or fourth most common cause of nosocomial bloodstream infections in the U.S. In aggregate, candidemia is associated with an overall mortality in excess of 40%. In the last decade, there has been a progressive rise in azole resistance among Candida species. As an example, rates of resistance to fluconazole and voriconazole for C. glabrata exceed 20-30% in many centers; fluconazole resistance among C. albicans exceeds 10% in several larger medical centers. Echinocandins, generally thought to be active against most Candida species, have emerged as drugs of first choice for most patients with invasive candidiasis. Unfortunately, antifungal resistance is emerging to this class of antifungals and resistance rates exceeding 5% are reported at some centers. An even more ominous development relates to associated mortality and antifungal resistance among pathogenic molds. Patients with invasive aspergillosis and mucormycosis have associated mortality as high as 70%. In addition, broad spectrum azole resistance among Aspergillus species has recently been described in the Netherlands and has emerged as a major concern among many European experts. Recent surveys among cancer patients in the United Kingdom and parts of Western Europe suggest that as many as 28% of clinically relevant Aspergillus isolates are azole resistant. While this has yet to be recognized as a major phenomenon in the U.S., it is only a matter of time before multi-azole resistance becomes a major problem for immune-compromised patients in the U.S. due to the highly global nature of our society. IDSA hopes that these comments are useful to FDA as the agency moves forward to develop the list of qualifying pathogens. Should you have any questions, please contact Amanda Jezek, IDSA s Director of Government Relations at ajezek@idsociety.org or Sincerely, David A. Relman, MD FIDSA President
2013 Indiana Healthcare Provider and Hospital Administrator Multi-Drug Resistant Organism Survey
2013 Indiana Healthcare Provider and Hospital Administrator Multi-Drug Resistant Organism Survey Antibiotic resistance is a global issue that has significant impact in the field of infectious diseases.
More informationANTIBIOTIC RESISTANCE THREATS. in the United States, 2013
ANTIBIOTIC RESISTANCE THREATS in the United States, 2013 TABLE OF CONTENTS Foreword... 5 Executive Summary.... 6 Section 1: The Threat of Antibiotic Resistance... 11 Introduction.... 11 National Summary
More informationSubmitted via: http://www.regulations.gov
May 29, 2015 Submitted via: http://www.regulations.gov Andrew Slavitt Acting Administrator Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services 7500 Security Boulevard
More informationHialeah Nursing and Rehabilitation Center Combines Technology and Best Practices to Improve Infection Control Specific to C.diff
RESEARCH ARTICLE Page 1 of 5 Hialeah Nursing and Rehabilitation Center Combines Technology and Best Practices to Improve Infection Control Specific to C.diff ABSTRACT RB Health Partners, Inc., June 24,
More informationFrequently Asked Questions
Guidelines for Testing and Treatment of Gonorrhea in Ontario, 2013 Frequently Asked Questions Table of Contents Background... 1 Treatment Recommendations... 2 Treatment of Contacts... 4 Administration
More informationNational Quality Forum (NQF) Endorsed Set of 34 Safe Practices*
NQF Endorsed Set of Safe Practices (released 2009) 1. Leadership Structures and Systems Leadership structures and systems must be established to ensure that there is organization-wide awareness of patient
More informationChapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
More informationTargeted Testing for Tuberculosis Infection
Targeted Testing for Tuberculosis Infection CONTENTS Introduction... 3.2 Purpose... 3.2 Policy... 3.2 When to Conduct Targeted Testing... 3.3 Approaches to increasing targeted testing and treatment for
More informationPrinciples of Disease and Epidemiology. Copyright 2010 Pearson Education, Inc.
Principles of Disease and Epidemiology Pathology, Infection, and Disease Disease: An abnormal state in which the body is not functioning normally Pathology: The study of disease Etiology: The study of
More informationNo. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER 5 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008
COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9637/08 SAN 88 DENLEG 52 VETER 7 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER
More informationAntibiotic resistance does it matter in paediatric clinical practice? Jette Bangsborg Department of Clinical Microbiology Herlev Hospital
Antibiotic resistance does it matter in paediatric clinical practice? Jette Bangsborg Department of Clinical Microbiology Herlev Hospital Background The Department of Clinical Microbiology at Herlev Hospital
More informationTuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
More informationBorderless Diseases By Sunny Thai
Borderless Diseases By Sunny Thai Millennium Development Goal #6 6. Combat HIV/AIDS, malaria and other borderless diseases. A. Halt and begin reversing spread of HIV by 2015. B. Achieve universal access
More informationEmerging Infectious Disease (4): Drug-Resistant Tuberculosis
S67 Drug-Resistant Tuberculosis Emerging Infectious Disease (4): Drug-Resistant Tuberculosis Chi-Fang You, MD; Han-Ping Ma, MD; Tzong-Luen Wang, MD, PhD; Aming Chor-Min Lin, MD Abstract Before the discovery
More informationAntimicrobial Resistance and Human Health
Antimicrobial Resistance and Human Health Dearbháile Morris, Discipline of Bacteriology, School of Medicine, National University of Ireland, Galway The microbial world The is a gene Talk cloud in a The
More informationAntimicrobial Stewardship Programs
A Hospital Pharmacist s Guide to Antimicrobial Stewardship Programs For more information on antimicrobial stewardship, please visit this initiative s website at www.ashpadvantage.com/stewardship Developed
More informationNATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA
NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA MARCH 2015 Table of Contents Executive Summary................................ 2 Introduction................................... 4 Goals
More informationIntroduction to Infection Control
CHAPTER 3 Introduction to Infection Control George Byrns and Mary Elkins Learning Objectives 1 Define terms used in infection control. 2. Review significant risk factors for infection. 3. Identify the
More informationNational Quality Forum Safe Practices for Better Healthcare
National Quality Forum Safe Practices for Better Healthcare UCLA Health System advocates the National Quality Forum (NQF) endorsed safe practices.this set of safe Practices encompasses 34 practices that
More informationGUIDELINES EXECUTIVE SUMMARY
GUIDELINES Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship Timothy
More informationClostridium difficile Infection (CDI) Gail Bennett, RN, MSN, CIC
Clostridium difficile Infection (CDI) Gail Bennett, RN, MSN, CIC 1 Clostridium difficile (C.difficile) Antibiotic induced diarrhea Can cause pseudomembranous colitis Most common cause of acute infectious
More informationManagement of Extended Spectrum Beta- Lactamase (ESBL) Producing Enterobacteriaceae in health care settings
Management of Extended Spectrum Beta- Lactamase (ESBL) Producing Enterobacteriaceae in health care settings Dr. Mary Vearncombe PIDAC-IPC February 2012 Objectives: To provide an overview of the RP/AP Annex
More informationAntimicrobial Stewardship for Hospital Acquired Infection Prevention: Focus on C. difficile infection
Antimicrobial Stewardship for Hospital Acquired Infection Prevention: Focus on C. difficile infection Emi Minejima, PharmD Assistant Professor of Clinical Pharmacy USC School of Pharmacy minejima@usc.edu
More informationGuidelines for Antimicrobial Stewardship in Hospitals in Ireland. A Strategy for the Control of Antimicrobial Resistance in Ireland
A Strategy for the Control of Antimicrobial Resistance in Ireland Guidelines for Antimicrobial Stewardship in Hospitals in Ireland Hospital Antimicrobial Stewardship Working Group Guidelines for Antimicrobial
More informationNosocomial Antibiotic Resistance in Multiple Gram-Negative Species: Experience at One Hospital with Squeezing the Resistance Balloon at Multiple Sites
INVITED ARTICLE HEALTHCARE EPIDEMIOLOGY Robert A. Weinstein, Section Editor Nosocomial Antibiotic Resistance in Multiple Gram-Negative Species: Experience at One Hospital with Squeezing the Resistance
More information4.06. Infection Prevention and Control at Long-term-care Homes. Chapter 4 Section. Background. Follow-up on VFM Section 3.06, 2009 Annual Report
Chapter 4 Section 4.06 Infection Prevention and Control at Long-term-care Homes Follow-up on VFM Section 3.06, 2009 Annual Report Background Long-term-care nursing homes and homes for the aged (now collectively
More informationPRIORITY RESEARCH TOPICS
PRIORITY RESEARCH TOPICS Understanding all the issues associated with antimicrobial resistance is probably impossible, but it is clear that there are a number of key issues about which we need more information.
More informationReview of Healthcare-Associated Infection (HAI) and Multidrug-Resistant Organism (MDRO) Reporting Requirements in the United States PRESENTED BY:
Review of Healthcare-Associated Infection (HAI) and Multidrug-Resistant Organism (MDRO) Reporting Requirements in the United States PRESENTED BY: BYRAN DAI MASTERS OF HEALTH SCIENCE CANDIDATE 14 JHSPH
More informationUdbredelse og betydning af resistente bakterier: Fokus på spredning fra dyr til mennesker
Udbredelse og betydning af resistente bakterier: Fokus på spredning fra dyr til mennesker Frank M. Aarestrup (fmaa@food.dtu.dk) Importance of the food animal reservoir for human health Different estimates
More informationRecommendations for the control of Multi-drug resistant Gram-negatives: carbapenem resistant Enterobacteriaceae. November 2013
Recommendations for the control of Multi-drug resistant Gram-negatives: carbapenem resistant Enterobacteriaceae November 2013 ISBN: Print: 978-1-921983-55-9 Electronic: 978-1-921983-56-6 Suggested citation:
More informationC-Difficile Infection Control and Prevention Strategies
C-Difficile Infection Control and Prevention Strategies Adrienne Mims, MD MPH VP, Chief Medical Officer Adrienne.Mims@AlliantQuality.org 1/18/2016 1 Disclosure This educational activity does not have commercial
More informationTHIS IS AN OFFICIAL NH DHHS HEALTH ALERT
THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network Health.Alert@nh.gov August 13, 2015 1400 EDT (2:00 PM EDT) NH-HAN 20150813 Updated Centers for Disease Control (CDC)
More informationGeneral Trends in Infectious Disease
General Trends in Infectious Disease Four phenomena underline the increase in ID problems: Aging population Increasing numbers of immunocompromised patients Increased mobility of the population Newly emerging
More informationASP 101. What is Antimicrobial Stewardship?
ASP 101 What is Antimicrobial Stewardship? Objectives To describe the rationale for antimicrobial stewardship; To state the definition and goals of antimicrobial stewardship; To identify the important
More informationSolid Organ Transplantation
Solid Organ Transplantation Infection Prevention And Control Transplant Atlantic 2011 October 13/2011 Kathy Hart Introduction In the past several years, the drugs that we use, the surgeries themselves,
More informationAntibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis
Antibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis ANTIBIOTIC-ASSOCIATED DIARRHEA Disturbance of the normal colonic microflora Leading to alterations in bacterial degradation
More informationThe National Antimicrobial Resistance Monitoring System (NARMS)
The National Antimicrobial Resistance Monitoring System (NARMS) Strategic Plan 2012-2016 Table of Contents Background... 2 Mission... 3 Overview of Accomplishments, 1996-2011... 4 Strategic Goals and Objectives...
More informationUrinary Tract Infections
Urinary Tract Infections Leading cause of morbidity and health care expenditures in persons of all ages. An estimated 50 % of women report having had a UTI at some point in their lives. 8.3 million office
More informationTigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
Brief Original Article Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae Fernando Pasteran, Celeste Lucero, Melina Rapoport, Leonor Guerriero,
More informationWorld Health Organization Department of Communicable Disease Surveillance and Response
WHO/CDS/CSR/DRS/2001.7 Infection control programmes to contain antimicrobial resistance Lindsay E. Nicolle World Health Organization Department of Communicable Disease Surveillance and Response This document
More informationThe opinions expressed herein are our own and do not necessarily reflect the views of The Johns Hopkins University.
Page 1 of 5 Johns Hopkins Center for a Livable Future 615 North Wolfe Street, W7010 Baltimore, MD 21205 July 12, 2012 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationJune 10, 2015. Dear Mr. Slavitt:
1275 K Street, NW, Suite 1000 Washington, DC 20005-4006 Phone: 202/789-1890 Fax: 202/789-1899 apicinfo@apic.org www.apic.org June 10, 2015 Andrew M. Slavitt Acting Administrator Centers for Medicare &
More informationAddressing the challenge of healthcare associated infections (HCAIs) in Europe
POSITION PAPER 05 January 2011 Addressing the challenge of healthcare associated infections (HCAIs) in Europe A Call for Action Page 1 of 8 A holistic approach to combating HCAIs in Europe We must rise
More informationTB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
More informationGlobal Spread of Carbapenemase- Producing Klebsiella pneumoniae
Global Spread of Carbapenemase- Producing Klebsiella pneumoniae These pathogens arose in the mid-1990s and continue to spread, leaving few options for treating infected patients John Quale John Quale is
More informationTuberculosis. Getting Healthy, Staying Healthy
Tuberculosis Getting Healthy, Staying Healthy U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases Tuberculosis Getting Healthy,
More informationTUBERCULOSIS CONTROL INDIA
TUBERCULOSIS CONTROL INDIA In terms of population coverage, India now has the second largest DOTS (Directly Observed Treatment, Short course) programme in the world. However, India's DOTS programme is
More informationRecommendations for Metrics for Multidrug-Resistant Organisms in Healthcare Settings: SHEA/HICPAC Position Paper
infection control and hospital epidemiology october 2008, vol. 29, no. 10 shea/hicpac position paper Recommendations for Metrics for Multidrug-Resistant Organisms in Healthcare Settings: SHEA/HICPAC Position
More informationControversies in Hospital Medicine: Antifungal Therapy. Empiric Therapy, Combination Therapy, and the Question of Central Venous Catheters
Controversies in Hospital Medicine: Antifungal Therapy Empiric Therapy, Combination Therapy, and the Question of Central Venous Catheters Douglas Fish, Pharm.D. Professor of Pharmacy, University of Colorado
More informationTuberculosis: FAQs. What is the difference between latent TB infection and TB disease?
Tuberculosis: FAQs What is TB disease? Tuberculosis (TB) is a disease caused by bacteria (germs) that are spread from person to person through the air. TB usually affects the lungs, but it can also affect
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Treatment of Latent Tuberculosis Infection and Tube rc ulos is Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National
More information2011 PROGRESS TOWARDS IMPLEMENTATION OF: A PUBLIC HEALTH ACTION PLAN TO COMBAT ANTIMICROBIAL RESISTANCE
2011 PROGRESS TOWARDS IMPLEMENTATION OF: A PUBLIC HEALTH ACTION PLAN TO COMBAT ANTIMICROBIAL RESISTANCE Interagency Task Force on Antimicrobial Resistance Co-Chairs: Centers for Disease Control and Prevention
More informationDr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015
TB burden and treatment guidelines Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 Outline Latest epidemiological data Global programme
More informationC. difficile Infections
C. difficile Infections Introduction C. difficile is a type of bacteria that can cause diarrhea and infection of the colon. This bacterium is more likely to infect patients at hospitals and other healthcare
More informationUrinary Tract Infections
Urinary Tract Infections Overview A urine culture must ALWAYS be interpreted in the context of the urinalysis and patient symptoms. If a patient has no signs of infection on urinalysis, no symptoms of
More informationSECURING NEW DRUGS FOR FUTURE GENERATIONS: THE PIPELINE OF ANTIBIOTICS
SECURING NEW DRUGS FOR FUTURE GENERATIONS: THE PIPELINE OF ANTIBIOTICS THE REVIEW ON ANTIMICROBIAL RESISTANCE CHAIRED BY JIM O NEILL MAY 2015 2 CONTENTS FOREWORD.... 1 EXECUTIVE SUMMARY....2 1. WHICH NEW
More informationDrug-resistant Tuberculosis
page 1/6 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Context - Tuberculosis (TB) is an infectious disease that affects a growing number of
More informationPatient Education CONTENTS. Introduction... 12.2
CONTENTS Introduction... 12.2 Purpose... 12.2 General Guidelines... 12.3 Language and Comprehension Barriers... 12.4 Education Topics... 12.5 Medical Diagnosis... 12.5 Contact Investigation... 12.6 Isolation...
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
More informationLab ID Events MRSA Bloodstream Infection and C. difficile
Lab ID Events MRSA Bloodstream Infection and C. difficile MDRO and CDI Module Methicillin-resistant Staphylococcus (MRSA), Vancomycinresistant Enterococcus(VRE), certain gram negative bacilli, Clostridium
More informationMODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section
More informationPublic Health is Public Safety. Bonnie J. Sorensen, MD, MBA Florida Department of Health in Volusia County October 25, 2013
Public Health is Public Safety Bonnie J. Sorensen, MD, MBA Florida Department of Health in Volusia County October 25, 2013 Mission Statement To Protect, promote and improve the health of all people in
More informationNursing college, Second stage Microbiology Dr.Nada Khazal K. Hendi L14: Hospital acquired infection, nosocomial infection
L14: Hospital acquired infection, nosocomial infection Definition A hospital acquired infection, also called a nosocomial infection, is an infection that first appears between 48 hours and four days after
More informationDART 2020. Fighting antibiotic resistance for the good of both humans and animals
DART 2020 Fighting antibiotic resistance for the good of both humans and animals DART 2020 Fighting antibiotic resistance for the good of both humans and animals 3 DART 2020 With many infectious diseases,
More informationAdministrative agreements on antibiotic resistance in healthcare
Administrative agreements on antibiotic resistance in healthcare Introduction Antibiotics are primarily needed to control bacterial infections. Additionally, antibiotics are indispensable for safety in
More informationTuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
More informationCONTROL AND PREVENTION OF ENTERIC FEVER: POLICY AND PRACTICE IN WHO SEARO
CONTROL AND PREVENTION OF ENTERIC FEVER: POLICY AND PRACTICE IN WHO SEARO Professor Lalitha Mendis 8 th International Conference on Typhoid fever And Other Invasive Salmonelloses 1-2 March 2013 WHO Position
More informationFrequently Asked Questions
Frequently Asked Questions Testing for Gonorrhea Q1: What test should be completed for accurately diagnosing gonorrhea? A1: Testing is done with either a culture or a NAAT (nucleic acid amplification test).
More informationPhiladelphia TB Newsletter
Philadelphia Department of Public Health Philadelphia TB Newsletter Volume 6, 6, Issue Issue 1 1 WORLD TB DAY EDITION Spring 2012 500 S. Broad Street, 2nd Floor Philadelphia, PA 19146 Michael Nutter Mayor
More informationChapter 21. What Are HIV and AIDS?
Section 1 HIV and AIDS Today What Are HIV and AIDS? Human immunodeficiency virus (HIV) is the virus that primarily affects cells of the immune system and that causes AIDS. Acquired immune deficiency syndrome
More informationhealthcare associated infection 1.2
healthcare associated infection A C T I O N G U I D E 1.2 AUSTRALIAN SAFETY AND QUALITY GOALS FOR HEALTH CARE What are the goals? The Australian Safety and Quality Goals for Health Care set out some important
More informationChapter 6 Treatment of Tuberculosis Disease
Chapter 6 Treatment of Tuberculosis Disease Table of Contents Chapter Objectives.... 139 Introduction.... 141 Treatment and Monitoring Plan.... 143 Adherence Strategies... 143 TB Disease Treatment Regimens....
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
More informationObjective 1A: Increase the adoption and effective use of health IT products, systems, and services
1275 K Street, NW, Suite 1000 Washington, DC 20005-4006 Phone: 202/789-1890 Fax: 202/789-1899 apicinfo@apic.org www.apic.org February 4, 2015 Karen DeSalvo, MD, MPH, MSc National Coordinator for Health
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More informationCh 14: Principles of Disease and Epidemiology
Ch 14: Principles of Disease and Epidemiology Learning Objectives Define pathology, etiology, infection, and disease Explain the difference between normal, transient, and opportunistic microbes Compare
More informationMerry King was a 48-year-old special education teacher in the
Stevia: sweet...but how safe? p. 9 Eat slowly, eat less, p. 8 Is chocolate a health food? p. 12 OCTOBER 2008 $2.50 CENTER FOR SCIENCE IN THE PUBLIC INTEREST Photo: Eric Erbe. Courtesy U.S. Department of
More informationPractice Guidelines. Updated Guideline on Diagnosis and Treatment of Intra-abdominal Infections
Updated Guideline on Diagnosis and Treatment of Intra-abdominal Infections CARRIE ARMSTRONG Guideline source: Surgical Infection Society, Infectious Diseases Society of America Literature search described?
More informationMETHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMMUNITY ACQUIRED vs. HEALTHCARE ASSOCIATED
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMMUNITY ACQUIRED vs. HEALTHCARE ASSOCIATED Recently, there have been a number of reports about methicillin-resistant Staph aureus (MRSA) infections
More information3.0 Treatment of Infection
3.0 Treatment of Infection Antibiotics and Medicine National Curriculum Link SCN 3-13b SCN 3-20b HWB 3-15a HWB 3-16a HWB 3-17a Learning Outcomes All students will know: Most common infections will get
More informationTB preventive therapy in children. Introduction
TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are
More informationJune 25, 2012. Dear Acting Administrator Tavenner,
June 25, 2012 Marilyn B. Tavenner, RN, Acting Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-1588-P P.O. Box 8011 Baltimore, MD 21244-1850
More informationRESEARCH AGENDA ON DRUG RESISTANT TUBERCULOSIS With A Focus On Scaling-up Programmes
RESEARCH AGENDA ON DRUG RESISTANT TUBERCULOSIS With A Focus On Scaling-up Programmes Background The Working Group on MDR-TB is an inter-institutional working group involving institutions/agencies and experts
More informationU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention Division of Tuberculosis Elimination Public
More informationReport by the Comptroller and Auditor General. The Management and Control of Hospital Acquired Infection in Acute NHS Trusts in England
Report by the Comptroller and Auditor General The Management and Control of Hospital Acquired Infection in Acute NHS Trusts in England HC 230 Session 1999-00 17 February 2000 Report by the Comptroller
More informationSHEA Position Paper. Vol. 18 No. 4 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY 275
Vol. 18 No. 4 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY 275 SHEA Position Paper Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention
More informationA Practical Guide to Diagnosis and Treatment of Infection in the Outpatient Setting Diagnosis and Treatment of Urinary Tract Infections
A Practical Guide to Diagnosis and Treatment of Infection in the Outpatient Setting Diagnosis and Treatment of Urinary Tract Infections By Gary R. Skankey, MD, FACP, Infectious Disease, Las Vegas, NV Sponsored
More informationDevelop an understanding of the differential diagnosis of pseudomembranous colitis
Update on Clostridium difficile Colitis Clostridium difficile infection has recently emerged in populations without any known risk factors. This presentation will focus on the historical background, diagnosis,
More informationMEDICAL MICROBIOLOGY 603 OR POPULATION HEALTH SCIENCES 603 CLINICAL AND PUBLIC HEALTH MICROBIOLOGY January 18-May 6, 2011
MEDICAL MICROBIOLOGY 603 OR POPULATION HEALTH SCIENCES 603 CLINICAL AND PUBLIC HEALTH MICROBIOLOGY January 18-May 6, 2011 Lectures: M, W, F 1:20-2:30 P.M. ( All lectures will be ~ 70 Minutes ) Office Hours
More informationCertofix protect More certainty, more safety, more success
Certofix protect More certainty, more safety, more success Highly effective, long-term protection against catheter infection Central Venous Catheters Antimicrobial modified hydrophilic surface We help
More informationClostridium Difficile colitismore virulent than ever ECHO- Sept 17, 2015
Clostridium Difficile colitismore virulent than ever ECHO- Sept 17, 2015 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis MMWR-
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationTele-audiology monitoring for MDR-TB: a national programme. Dirk Koekemoer (MD) Chairman GeoAxon Tele Health
Tele-audiology monitoring for MDR-TB: a national programme Dirk Koekemoer (MD) Chairman GeoAxon Tele Health Norbert Ndjeka (MD) Director MDR-TB National DoH South Africa is the third highest tuberculosis
More informationExpedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon
Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon Oregon Health Authority Center for Public Health Practice HIV/STD/TB Section Principles of
More informationNASAL COLONIZATION BY MICROORGANISMS IN NURSING PROFESSIONALS IN UNITS SPECIALIZING IN HIV/AIDS
University of Sa o Paulo at Ribeira o Preto College of Nursing. WHO Collaborating Centre for Nursing Research Development. Ribeirão Preto (SP), Brazil. RENAIDST Rede Nacional NASAL COLONIZATION BY MICROORGANISMS
More informationMN HAI Prevention Plan 1
Healthcare Associated Infections Plan Minnesota Department of Health Healthcare Associated Infections Program Introduction In response to the increasing concerns about the public health impact of healthcare-associated
More informationThe Immune System and Disease
Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction
More informationGoal 1; Objective B: Improve health care quality and patient safety: Performance measure
TRUST FOR AMERICA S HEALTH COMMENTS ON THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) DRAFT STRATEGIC PLAN 2010 2015 Goal 1; Objective B: Improve health care quality and patient safety: Performance
More informationTuberculosis Exposure Control Plan for Low Risk Dental Offices
Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.
More information